JPH09505034A - 5α−レダクターゼ阻害剤によるアンドロゲン脱毛症の治療方法 - Google Patents
5α−レダクターゼ阻害剤によるアンドロゲン脱毛症の治療方法Info
- Publication number
- JPH09505034A JPH09505034A JP7511986A JP51198695A JPH09505034A JP H09505034 A JPH09505034 A JP H09505034A JP 7511986 A JP7511986 A JP 7511986A JP 51198695 A JP51198695 A JP 51198695A JP H09505034 A JPH09505034 A JP H09505034A
- Authority
- JP
- Japan
- Prior art keywords
- day
- dose
- reductase
- inhibitor
- alopecia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.治療を必要とする者に5.0mg/日未満の用量の5α−レダクターゼ2阻 害剤を投与することからなるアンドロゲン脱毛症の治療方法。 2.用量が約0.01〜3.0mg/日である請求項1に記載の方法。 3.用量が約0.05〜1.0mg/日である請求項1に記載の方法。 4.用量が約0.05mg/日である請求項1に記載の方法。 5.用量が約0.2mg/日である請求項1に記載の方法。 6.アンドロゲン脱毛症が男性部分禿頭症である請求項1に記載の方法。 7.5α−レダクターゼ2阻害剤を経口投与する請求項1に記載の方法。 8.5α−レダクターゼ2阻害剤を局所投与する請求項1に記載の方法。 9.5α−レダクターゼ2阻害剤が、構造式I (式中、 R1は水素、メチル又はエチルであり; R2は1〜12個の炭素を有する直鎖及び分枝鎖アルキル又は1〜2個の炭素原 子を有する1個以上の低級アルキル置換基及び/もしくは1個以上のハロゲン( Cl,F又はBr)置換基を任意に含む単環式アリールの中から選択される炭化 水素ラジカルであり; R′は水素又はメチルであり; R″は水素又はβ−メチルであり; その医薬的に許容可能な塩で表される請求項1に記載の方法。 10.5α−レダクターゼ2阻害剤が、構造式II (式中、 R1は水素又はメチルであり; R3は4〜8個の炭素を有する分枝鎖アルキルである)の化合物又はその医薬的 に許容可能な塩で表される請求項1に記載の方法。 11.治療を必要とする者に5.0mg/日未満の用量の17β−(N−t−ブ チルカルバモイル)−4−アザ−5α−アンドロスト−1−エン−3−オンを投 与することからなるアンドロゲン脱毛症の治療方法。 12.アンドロゲン脱毛症が男性部分禿頭症である請求項11に記載の方法。 13.用量が約0.01〜3.0mg/日である請求項11に 記載の方法。 14.用量が約0.05〜1.0mg/日である請求項11に記載の方法。 15.用量が約0.05mg/日である請求項11に記載の方法。 16.用量が約0.2mg/日である請求項11に記載の方法。 17.17β−(N−t−ブチルカルバモイル)−4−アザ−5α−アンドロス ト−1−エン−3−オンを局所投与する請求項11に記載の方法。 18.17β−(N−t−ブチルカルバモイル)−4−アザ−5α−アンドロス ト−1−エン−3−オンを経口投与する請求項11に記載の方法。 19.用量が約0.2mg/日である請求項18に記載の方法。 20.用量が約0.05mg/日である請求項18に記載の方法。 21.治療を必要とする者に5.0mg/日末満の用量の5α−レダクターゼ2 阻害剤を投与することからなるアンドロゲン脱毛症の進行を阻止し、回復させる 方法。 22.治療を必要とする者に5.0mg/日未満の用量の5α −レダクターゼ2阻害剤を投与することからなるヒト頭皮中の5α−ジヒドロテ トステロンのレベルを低下させる方法。 23.用量が約0.01〜3.0mg/日である請求項22に記載の方法。 24.用量が約0.05〜1.0mg/日である請求項22に記載の方法。 25.用量が約0.05mg/日である請求項22に記載の方法。 26.用量が約0.2mg/日である請求項22に記載の方法。 27.用量が約1.0mg/日である請求項22に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13852093A | 1993-10-15 | 1993-10-15 | |
US214,905 | 1994-03-17 | ||
US138,520 | 1994-03-17 | ||
US08/214,905 US5547957A (en) | 1993-10-15 | 1994-03-17 | Method of treating androgenic alopecia with 5-α reductase inhibitors |
PCT/US1994/011507 WO1995010284A1 (en) | 1993-10-15 | 1994-10-11 | Method of treating androgenic alopecia with 5-alpha reductase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09505034A true JPH09505034A (ja) | 1997-05-20 |
JP3058351B2 JP3058351B2 (ja) | 2000-07-04 |
Family
ID=26836279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7511986A Expired - Lifetime JP3058351B2 (ja) | 1993-10-15 | 1994-10-11 | 5α−レダクターゼ阻害剤によるアンドロゲン脱毛症の治療方法 |
Country Status (28)
Country | Link |
---|---|
US (3) | US5824686A (ja) |
EP (1) | EP0724444B1 (ja) |
JP (1) | JP3058351B2 (ja) |
CN (1) | CN1096861C (ja) |
AT (1) | ATE156358T1 (ja) |
BG (1) | BG62756B1 (ja) |
BR (1) | BR9407824A (ja) |
CA (1) | CA2173457C (ja) |
CY (1) | CY2071B1 (ja) |
CZ (1) | CZ287104B6 (ja) |
DE (1) | DE69404854T2 (ja) |
DK (1) | DK0724444T3 (ja) |
DZ (1) | DZ1817A1 (ja) |
ES (1) | ES2105774T3 (ja) |
FI (1) | FI961632A0 (ja) |
GR (1) | GR3024375T3 (ja) |
HR (1) | HRP940673B1 (ja) |
HU (1) | HU227861B1 (ja) |
IL (1) | IL111293A (ja) |
LV (1) | LV12103B (ja) |
MX (1) | MXPA99002296A (ja) |
NO (1) | NO309927B1 (ja) |
NZ (1) | NZ275678A (ja) |
PL (1) | PL184930B1 (ja) |
RO (1) | RO116864B1 (ja) |
SK (1) | SK282352B6 (ja) |
TW (1) | TW382595B (ja) |
WO (1) | WO1995010284A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547957A (en) * | 1993-10-15 | 1996-08-20 | Merck & Co., Inc. | Method of treating androgenic alopecia with 5-α reductase inhibitors |
NL1005445C2 (nl) * | 1997-03-05 | 1998-09-21 | Gho St Holding B V | Werkwijze voor het vermenigvuldigen van haar. |
US5935968A (en) | 1997-03-17 | 1999-08-10 | Merck & Co., Inc. | Methods for treating polycystic ovary syndrome |
CA2298851A1 (en) | 1997-07-29 | 1999-02-11 | Sankyo Company Limited | Remedial agent for baldness and other diseases |
US6348348B1 (en) * | 1998-04-07 | 2002-02-19 | The Carnegie Institution Of Washington | Human hairless gene and protein |
IL124764A0 (en) * | 1998-06-04 | 1999-01-26 | Univ Ben Gurion | Topical composition for treatment of baldness |
WO2000030636A1 (en) | 1998-11-20 | 2000-06-02 | The General Hospital Corporation | Use of pyrethroid compounds to promote hair growth |
AU6087700A (en) * | 1999-07-15 | 2001-02-05 | Procter & Gamble Company, The | Nitrogen-containing steroid compounds and their use to regulate hair growth |
ES2158828B1 (es) * | 2000-02-22 | 2002-03-16 | Tobajas Maximo Gomez | Metodo cosmetico para estimular el nacimiento y el crecimiento del cabello. |
WO2002019974A1 (fr) * | 2000-09-04 | 2002-03-14 | Ravi Shrivastava | Associations synergiques a base de plantes pour traiter la chute des cheveux |
DK1262177T3 (da) * | 2001-05-31 | 2006-11-20 | Pfizer Prod Inc | Medicinsk brug af thyromimetiske forbindelser til behandling af hårtab og kompositioner |
US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
BR0309435A (pt) | 2002-04-24 | 2005-02-15 | Boehringer Ingelheim Pharma | Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda |
FR2954124B1 (fr) * | 2009-12-18 | 2012-04-06 | Fabre Pierre Dermo Cosmetique | Utilisation du 2,3-dihydroxypropyl dodecanoate pour le traitement de la seborrhee |
BR112013002697A2 (pt) * | 2010-08-05 | 2016-05-31 | Legacy Healthcare Holding Ltd | método para estimular o crescimento do cabelo |
BR112013018679B1 (pt) * | 2011-01-21 | 2022-04-12 | Igisu Co. Ltd. | Agente para o tratamento da alopecia e uso de um peptídeo natriurético do tipo c |
GB201102913D0 (en) | 2011-02-18 | 2011-04-06 | Univ Birmingham | Novel therapeutic |
WO2013040321A1 (en) * | 2011-09-15 | 2013-03-21 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
EP2703003A1 (en) | 2012-08-31 | 2014-03-05 | Probelte Biotecnologia S.L. | A pomegranate extract and compositions containing pomegranate polyphenols for treating or preventing diseases or physiopathological conditions associated with an excessive gene expression and/or physiological activity of interleukin-6 |
HRP20211765T1 (hr) * | 2017-06-16 | 2022-02-18 | Capilli Med Gmbh | Kompozicija za sprječavanje opadanja kose i za pospješivanje rasta kose |
US11331300B2 (en) * | 2017-12-22 | 2022-05-17 | Richard Postrel | Reversing baldness through follicle regeneration |
EA202290013A1 (ru) | 2019-06-28 | 2022-03-18 | Общество С Ограниченной Ответственностью "Регеус" | Средство для усиления роста волос |
FR3106058B1 (fr) * | 2020-01-09 | 2022-01-07 | Oreal | Procédé de traitement cosmétique |
CN113398263B (zh) * | 2021-08-06 | 2022-11-11 | 广东巧巧生物科技有限公司 | 一种治疗脱发的洗发水 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6365080B2 (ja) | 1984-02-27 | 1988-12-14 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377584A (en) * | 1978-04-13 | 1983-03-22 | Merck & Co., Inc. | 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors |
AU527030B2 (en) * | 1978-04-13 | 1983-02-10 | Merck & Co., Inc. | 4-aza-17-substituted-5a-androstan-3-ones |
US4396615A (en) * | 1981-06-24 | 1983-08-02 | Duke University | Method of treating androgen-related disorders |
US4885289A (en) * | 1983-12-12 | 1989-12-05 | Breuer Miklos M | Alteration of character of male beard growth |
US4760071A (en) * | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
IL74365A (en) * | 1984-02-27 | 1990-07-26 | Merck & Co Inc | 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it |
US5571817A (en) * | 1984-02-27 | 1996-11-05 | Merck & Co., Inc. | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
US4684635A (en) * | 1984-05-11 | 1987-08-04 | Norman Orentreich | Compositions and methods for inhibiting the action of androgens |
US5053403A (en) * | 1984-05-11 | 1991-10-01 | Norman Orentreich | Methods for treatment of male-pattern baldness |
EP0285382B1 (en) * | 1987-04-03 | 1994-04-13 | Merck & Co. Inc. | Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones |
US5228431A (en) * | 1990-04-26 | 1993-07-20 | Giarretto Ralph R | Drug-free method for treatment of the scalp for therapeutic purposes |
CA2085605C (en) * | 1990-08-10 | 2003-03-11 | Arthur Robert Diani | Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors |
US5175155A (en) * | 1991-10-07 | 1992-12-29 | Sterling Winthrop Inc. | Win 49596-finasteride method of use and compositions |
AU668181B2 (en) * | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | Ester derivatives of 4-aza-steroids |
US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
US5407944A (en) * | 1993-02-19 | 1995-04-18 | Goldman; Boris E. | Compositions and methods for promoting hair growth |
US5438061A (en) * | 1993-07-16 | 1995-08-01 | Merck & Co., Inc. | 7-substituted-δ4-6-azasteroid derivatives as 5α-reductase inhibitors |
TW369521B (en) * | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
US5547957A (en) * | 1993-10-15 | 1996-08-20 | Merck & Co., Inc. | Method of treating androgenic alopecia with 5-α reductase inhibitors |
US5708001A (en) * | 1993-12-17 | 1998-01-13 | Glaxo Wellcome Inc. | Substituted 6-azaandrostenones |
US5525608A (en) * | 1994-04-20 | 1996-06-11 | Merck & Co., Inc. | 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors |
US5512555A (en) * | 1994-07-21 | 1996-04-30 | Merck & Co., Inc. | Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one |
US5595996A (en) * | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
US5777134A (en) * | 1995-10-26 | 1998-07-07 | Merck & Co., Inc. | 4-oxa and 4-thia steriods |
US5849764A (en) * | 1995-12-14 | 1998-12-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US5756507A (en) * | 1995-12-14 | 1998-05-26 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US5780437A (en) * | 1995-12-14 | 1998-07-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
-
1994
- 1994-10-07 TW TW083109300A patent/TW382595B/zh not_active IP Right Cessation
- 1994-10-11 PL PL94316854A patent/PL184930B1/pl unknown
- 1994-10-11 RO RO96-00793A patent/RO116864B1/ro unknown
- 1994-10-11 AT AT94930701T patent/ATE156358T1/de active
- 1994-10-11 JP JP7511986A patent/JP3058351B2/ja not_active Expired - Lifetime
- 1994-10-11 WO PCT/US1994/011507 patent/WO1995010284A1/en active IP Right Grant
- 1994-10-11 SK SK448-96A patent/SK282352B6/sk not_active IP Right Cessation
- 1994-10-11 US US08/596,339 patent/US5824686A/en not_active Expired - Lifetime
- 1994-10-11 BR BR9407824A patent/BR9407824A/pt not_active Application Discontinuation
- 1994-10-11 HU HU9600976A patent/HU227861B1/hu unknown
- 1994-10-11 CZ CZ19961081A patent/CZ287104B6/cs not_active IP Right Cessation
- 1994-10-11 DE DE69404854T patent/DE69404854T2/de not_active Expired - Lifetime
- 1994-10-11 ES ES94930701T patent/ES2105774T3/es not_active Expired - Lifetime
- 1994-10-11 EP EP94930701A patent/EP0724444B1/en not_active Expired - Lifetime
- 1994-10-11 CN CN94194471A patent/CN1096861C/zh not_active Ceased
- 1994-10-11 CA CA002173457A patent/CA2173457C/en not_active Expired - Lifetime
- 1994-10-11 NZ NZ275678A patent/NZ275678A/en not_active IP Right Cessation
- 1994-10-11 DK DK94930701.1T patent/DK0724444T3/da active
- 1994-10-12 DZ DZ940107A patent/DZ1817A1/fr active
- 1994-10-12 HR HR08/214,905A patent/HRP940673B1/xx not_active IP Right Cessation
- 1994-10-13 IL IL11129394A patent/IL111293A/en not_active IP Right Cessation
-
1996
- 1996-02-14 US US08/601,497 patent/US5760046A/en not_active Expired - Fee Related
- 1996-04-12 FI FI961632A patent/FI961632A0/fi not_active Application Discontinuation
- 1996-04-15 NO NO961497A patent/NO309927B1/no not_active IP Right Cessation
- 1996-04-16 BG BG100510A patent/BG62756B1/bg unknown
-
1997
- 1997-08-07 GR GR970401888T patent/GR3024375T3/el unknown
-
1998
- 1998-03-12 LV LVP-98-49A patent/LV12103B/en unknown
- 1998-06-22 US US09/102,454 patent/US5981543A/en not_active Expired - Fee Related
- 1998-09-11 CY CY9802071A patent/CY2071B1/xx unknown
-
1999
- 1999-03-09 MX MXPA99002296A patent/MXPA99002296A/es active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6365080B2 (ja) | 1984-02-27 | 1988-12-14 |
Non-Patent Citations (26)
Title |
---|
JPN3013001635; DIANI A R: 'HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A STEROID 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び翻訳 VOL. 74, NO. 2, 1992, PAGES 345-350, THE EDOCRINE SOCIETY |
JPN3013001636; GORMLEY G J: 'EFFECTS OF FINASTERIDE (MK-906), A 5ALPHA-REDUCTASE INHIBITOR, ON CIRCULATING 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び翻訳 VOL. 70, NO. 4, 1990, PAGES 1136-1141, THE ENDOCRINE SOCIETY |
JPN3013001637; MACCONNELL J D: 'FINASTERIDE, AN INHIBITOR OF 5ALPHA-REDUCTASE, SUPPRESSES PROSTATIC 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び翻訳 VOL. 74, NO. 3, 1992, PAGES 505-508, THE ENDOCRINE SOCIETY |
JPN3013001638; VERMEULEN A: 'HORMONAL EFFECTS OF AN ORALLY ACTIVE 4-AZASTEROID INHIBITOR OF 5ALPHA-REDUCTASE IN HUMANS' THE PROSTATE 及び翻訳 VOL. 14, 1989, PAGES 45-53 |
JPN3013001639; OHTAWA M: 'PHARMACOKINETICS AND BIOCHEMICAL EFFICACY AFTER SINGLE AND MULTIPLE ORAL 以下備考' EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 及び翻訳 VOL. 16, NO. 1, 1991, PAGES 15-21 |
JPN3013001640; 特許・実用新案 審査基準 (抜粋) , 特許庁 |
JPN3014000110; 欧州特許公開0285382号公報及び訳文 , 19881005, 欧州特許庁 |
JPN3014000111; DIANI A R: 'HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A STEROID 5alpha-REDUCTASE 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び訳文 VOL. 74, NO. 2, 1992, PAGES 345-350, THE ENDOCRINE SOCIETY |
JPN3014000112; UNO H: 'STUMPTAILED MACAQUES AS A MODEL OF MALE-PATTERN BALDNESS' MODELS DERMATOL 及び訳文 VOL. 3, 1987, PAGES 159-169 |
JPN3014000113; STONER E: 'THE CLINICAL DEVELOPMENT OF A 5alpha-REDUCTASE IN HIBITOR, FINASTERIDE' J. STEROID BIOCHEM. MOLEC. BIOI. 及び抄訳 VOL. 37, NO. 3, 1990, PAGES 375-378, PERGAMON PRESS |
JPN3014000114; GORMLEY G J: 'THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA' THE NEW ENGLAND JOURNAL OF MEDICINE 及び抄訳 VOL 327, NO. 17, 19921022, PAGES 1185-1191, THE MASSACHUSETTS MEDICAL SOCIETY |
JPN3014000115; OHTAWA M: 'PHARMACOKINETICS AND BIOCHEMICAL EFFICACY AFTER SINGLE AND MULTIPLE ORAL ADMINISTRATION 以下備考' EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS 及び訳文 VOL. 16, NO. 1, 1991, PAGES 15-21 |
JPN3014000116; STONER E: 'THE CLINICAL EFFECTS OF A 5alpha-REDUCTASE INHIBITOR, FINASTRIDE, ON BENIGN PROSTATIC HYPERPLASIA' THE JOURNAL OF UROLOGY 及び抄訳 VOL. 147, 199205, PAGES 1298-1302, AMERICAN UROLOGICAL ASOCIATION, INC. |
JPN3014000117; GORMLEY G J: 'EFFECTS OF FINASTERIDE (MK-906), A 5alpha-REDUCTASE INHIBITOR, ON CIRCULATING ANDROGENS 以下備考' JOUNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び訳文 VOL. 70, NO. 4, 1990, PAGES 1136-1141, THE ENDOCRINE SOCIETY |
JPN3014000118; MCCONNELL J D: 'FINASTERIDE, AN INHIBITOR OF 5alpha-REDUCTASE, SUPPRESSES PROSTATIC DIHYDROTESTOSTERONE IN 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び訳文 VOL. 74, NO. 3, 1992, PAGES 505-508, THE ENDOCRINE SOCIETY |
JPN3014000119; VERMEULEN A: 'HORMONAL EFFECTS OF AN ORALLY ACTIVE 4-AZESTEROID INHIBITOR OF 5alpha-REDUCTASE IN HUMANS' THE PROSTATE 及び訳文 VOL. 14, 1989, PAGES 45-53, ALAN R. LISS, INC. |
JPN3014000120; SUDDUTH S L: 'EVALUATION OF NEW DRUGS FINASTERIDE: THE FIRST 5alpha-REDUCTASE INHIBITOR' PHARMACOTHERAPY 及び抄訳 VOL. 13, NO. 4, 1993, PAGES 309-329 |
JPN3014000121; RITTMASTER R S: 'THE EFFECTS OF N,N-DIETHYL-4-METHYL-3-OXO-4-AZA-5alpha-ANDROSTANE-17beta-CARBOXAMIDE, 以下備考' JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM 及び抄訳 VOL. 86, NO. 1, 1987, PAGES 188-193, THE ENDOCRINE SOCIETY |
JPN3014000122; 戸部満壽夫 他: 実験医学のめざす外挿 実験動物からヒトへ 第1版, 19840920, PAGES 66-75, (有)清至書院 |
JPN3014000123; 柳浦才三 他: 新版 図説薬理学 新版第2刷, 19840601, PAGES 9-10, (株)朝倉書店 |
JPN3014000124; 欧州特許公開0155096号公報及び抄訳 , 19850918, 欧州特許庁 |
JPN3014000125; 米国特許4760071号公報及び訳文 , 19880726, 米国特許商標庁 |
JPN3014000126; 薬科学大辞典編集委員会: 廣川 薬科学大辞典 第2版第4刷、縮刷版, 19930405, PAGES 1422-1423, 1440-1441, (株)廣川書店 |
JPN3014000127; FREIREICH E J: 'QUANTITATIVE COMPARISON OF TOXICITY OF ANTICANCER AGENTS IN MOUSE, RAT, HAMSTER, DOG 以下備考' CANCER CHEMOTHERAPY REPORTS 及び抄訳 VOL. 50, NO. 4, 196605, PAGES 219-244 |
JPN3014000128; '判決' 平成13年(行ケ)第285号特許取消決定取消請求事件 , 東京高等裁判所 |
JPN3014000129; '判決' 平成17年(行ケ)第10665号特許取消決定取消請求事件 , 知的財産高等裁判所 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6355649B1 (en) | Method of treating seborrhea with 5-α reductase inhibitors | |
JPH09505034A (ja) | 5α−レダクターゼ阻害剤によるアンドロゲン脱毛症の治療方法 | |
US20090123571A1 (en) | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | |
JPH09504553A (ja) | 5α−レダクターゼ阻害薬としての7−置換−4−アザ−ステロイド誘導体 | |
JPH11513380A (ja) | 5−αレダクターゼ阻害剤によるアンドロゲン性脱毛症の予防方法 | |
JPH11513684A (ja) | 16−置換−6−アザ−ステロイド5α−レダクターゼ阻害剤 | |
AU688395C (en) | Method of treating androgenic alopecia with 5-alpha reductase inhibitors | |
JPH11513711A (ja) | 17−アルキル−7−置換−4−アザステロイド誘導体 | |
RU2173152C2 (ru) | Способ лечения андрогенной алопеции ингибиторами 5-альфа-редуктазы | |
AU700565B2 (en) | 5-alpha-reductase inhibitor formulations | |
JPH0597684A (ja) | テストステロン 5αーレダクターゼ阻害剤 | |
MXPA06011870A (es) | Compuesto farmaceutico para tratar la perdida de cabello y la hiperplasia prostatica benigna. | |
SA94150323B1 (ar) | طريقة لمعالجة الصلع الأندروجيني بواسطة مثبطات إنزيم 5- ألفا رداكتاز | |
US20110136769A1 (en) | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | |
GB2279952A (en) | Naphthopyridine derivative 5alpha-reductase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
R150 | Certificate of patent or registration of utility model |
Ref document number: 3058351 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S201 | Request for registration of exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R314201 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S202 | Request for registration of non-exclusive licence |
Free format text: JAPANESE INTERMEDIATE CODE: R315201 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R315531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20200421 Year of fee payment: 20 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20200421 Year of fee payment: 20 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20200421 Year of fee payment: 20 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20200421 Year of fee payment: 20 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R157 | Certificate of patent or utility model (correction) |
Free format text: JAPANESE INTERMEDIATE CODE: R157 |
|
RVTR | Cancellation due to determination of trial for invalidation |